Key Players in the Obesity GLP-1 Market Novo Nordisk Eli Lilly and Company Amgen BoehringerIngelheim AstraZeneca Pfizer Roche Viking Therapeutics Structure Therapeutics Zealand Pharma Scope of the Report Obesity GLP-1 Market by Segments By Molecule Class: Semaglutide Tirzepatide Other GLP-1 Receptor Agonists By Route of Administration: Injectables Oral Formulations By Payer Type: Public Coverage Private Insurance and Self-Pay By Use-Case Framing: Weight Management Cardiovascular Risk Anchored By Region: North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Netherlands Rest of Europe East Asia China Japan South Korea South Asia and Pacific India Australia New Zealand Frequently Asked Questions How big is the obesity GLP-1 market in 2025
Bazot, M., Bharwani, N., Huchon, C., Kinkel, K., Cunha, T
We are not affiliated with Novo Nordisk or Eli Lilly and we do not supply their products, and their trademarks are their own
Moonrays 6
Rehydrate: Remember to stay hydrated
Para continuar, ingresa atu cuenta trace-id: b112abd2-af20-46d7-afff-d14b28770002 Usamos cookies para mejorar tu experiencia en Mercado Libre
